Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting
Tumori. 2023 Sep 29:3008916231202149. doi: 10.1177/03008916231202149. Online ahead of print.ABSTRACTAnaplastic Lymphoma Kinase (ALK) is a potent oncogenic driver of lung adenocarcinoma (LUAD). ALK is constitutively activated by gene fusion events between the ALK and other gene fusion partners in about 2-3% of LUADs, characterized by few other gene alterations. ALK-fusions are a druggable target through potent pharmacological inhibitors of tyrosine kinase activity. Thus, several ALK-TKIs (Tyrosine Kinase Inhibitors) of first-, second- and third-generation have been developed that improved the outcomes of ALK-rearranged LUAD...
Source: Tumori - September 29, 2023 Category: Cancer & Oncology Authors: Ugo Testa Germana Castelli Elvira Pelosi Source Type: research
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey
CONCLUSION: Our results raise some important issues concerning the evaluation of PD-L1 in the "real-life" setting, providing strategies for its implementation.PMID:37726962 | DOI:10.1177/03008916231196781 (Source: Tumori)
Source: Tumori - September 20, 2023 Category: Cancer & Oncology Authors: Bruna Cerbelli Alessio Cirillo Giulia Pomati Angelina Pernazza Andrea Ascione Simona Pisegna Annalinda Pisano Martina Leopizzi Maria Gemma Pignataro Leopoldo Costarelli Antonino Mul รจ Andrea Vecchione Piera Catalano Luigi Coppola Giuseppe Perrone Letizia Source Type: research
